Intragenic integration in DLC1 sustains factor VIII expression in primary human cells without insertional oncogenicity

Gene Therapy

Volumn 21, Issue 4, 2014, Pages 402-412

  Sivalingam, J ^a,b   Phan, T T ^a,c   Kon, O L ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c CellResearch Corporation   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; GENOMIC DNA; INTEGRASE; PHIC31 INTEGRASE; UNCLASSIFIED DRUG; DLC1 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL CYCLE; CELL THERAPY; CONTROLLED STUDY; DLC1 GENE; DNA MODIFICATION; DNA REPAIR; EPITHELIUM CELL; EX VIVO STUDY; GENE; GENE DOSAGE; GENE EXPRESSION; GENE LOCUS; GENE THERAPY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; UMBILICAL CORD; BIOSYNTHESIS; COPY NUMBER VARIATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; NUCLEOTIDE SEQUENCE; UMBILICAL VEIN ENDOTHELIAL CELL;

BASE SEQUENCE; DNA COPY NUMBER VARIATIONS; FACTOR VIII; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; GTPASE-ACTIVATING PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRASES; MUTAGENESIS, INSERTIONAL; TRANSFECTION; TRANSGENES; TUMOR SUPPRESSOR PROTEINS;

EID: 84897577406     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.11     Document Type: Article

References (46)

1. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
2. Gaspar H, Parsley K, Howe S, King D, Gilmour K, Sinclair J et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gam-maretroviral vector. The Lancet 2004; 364: 2181-2187.
3. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-458.
4. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by inser-tional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
5. Boztug K, Schmidt M, Schwarzer A, Banerjee PP, D́iez IA, Dewey RA et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010; 363: 1918-1927.
6. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818-823.
7. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118: 3132-3142.
8. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118: 3143-3150.
9. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16: 198-204.
10. Sadelain M, Papapetrou EP, Bushman FD. Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer 2011; 12: 51-58.
11. Chalberg TW, Portlock JL, Olivares EC, Thyagarajan B, Kirby PJ, Hillman RT et al. Integration specificity of phage phiC31 integrase in the human genome. J Mol Biol 2006; 357: 28-48.
12. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Calos MP, Khavari PA et al. PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bul-losa. Hum Gene Ther 2003; 14: 923-928.
13. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP et al. Stable nonviral genetic correction of inherited human skin disease. Nat Med 2002; 8: 1166-1170.
14. Ishikawa Y, Tanaka N, Murakami K, Uchiyama T, Kumaki S, Tsuchiya S et al. Phage phiC31 integrase-mediated genomic integration of the common cytokine receptor gamma chain in human T-cell lines. J Gene Med 2006; 8: 646-653.
15. Held PK, Olivares EC, Aguilar CP, Finegold M, Calos MP, Grompe M et al. In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. Mol Ther 2005; 11: 399-408.
16. Keravala A, Chavez CL, Hu G, Woodard LE, Monahan PE, Calos MP et al. Long-term phenotypic correction in factor IX knockout mice by using FC31 integrase-mediated gene therapy. Gene Therapy 2011; 18: 842-848.
17. Sivalingam J, Krishnan S, Ng WH, Lee SS, Phan TT, Kon OL et al. Biosafety assessment of site-directed transgene integration in human umbilical cord-lining cells. Mol Ther 2010; 18: 1346-1356.
18. Chavez CL, Keravala A, Chu JN, Farruggio AP, Cuéllar VE, Voorberg J et al. Long-term expression of human coagulation factor VIII in a tolerant mouse model using the jC31 integrase system. Hum Gene Ther 2012; 23: 390-398.
19. Bertoni C, Jarrahian S, Wheeler TM, Li Y, Olivares EC, Calos MP et al. Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration. Proc Natl Acad Sci USA 2006; 103: 419-424.
20. Thyagarajan B, Olivares EC, Hollis RP, Ginsburg DS, Calos MP. Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol Cell Biol 2001; 21: 3926-3934.
21. Doering CB, Denning G, Dooriss K, Gangadharan B, Johnston JM, Kerstann KW et al. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A. Mol Ther 2009; 17: 1145-1154.
22. Groth AC, Olivares EC, Thyagarajan B, Calos MP. A phage integrase directs efficient site-specific integration in human cells. Proc Natl Acad Sci USA 2000; 97: 5995-6000.
23. Liao YC, Lo SH. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol 2008; 40: 843-847.
24. Jiang Z, Huang Y, Sharfstein ST. Regulation of recombinant monoclonal antibody production in chinese hamster ovary cells: a comparative study of gene copy number, mRNA level, and protein expression. Biotechnol Prog 2006; 22: 313-318.
25. Wang GP, Garrigue A, Ciuffi A, Ronen K, Leipzig J, Berry C et al. DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucleic Acids Res 2008; 36: e49.
26. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC et al. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 1998; 58: 2196-2199.
27. Low JSW, Tao Q, Ng KM, Goh HK, Shu XS, Woo WL et al. A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Oncogene 2011; 30: 1923-1935.
28. Liu J, Jeppesen I, Nielsen K, Jensen TG. Phi c31 integrase induces chromosomal aberrations in primary human fibroblasts. Gene Therapy 2006; 13: 1188-1190.
29. Ehrhardt A, Engler JA, Xu H, Cherry AM, Kay MA. Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration. Hum Gene Ther 2006; 17: 1077-1094.
30. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
31. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
32. Hafez M, Hausner G. Homing endonucleases: DNA scissors on a mission. Genome 2012; 55: 553-569.
33. Palpant NJ, Dudzinski D. Zinc finger nucleases: looking toward translation. Gene Therapy 2013; 20: 121-127.
34. Kim E, Kim S, Kim DH, Choi BS, Choi IY, Kim JS et al. Precision genome engineering with programmable DNA-nicking enzymes. Genome Res 2012; 22: 1327-1333.
35. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 2013; 14: 49-55.
36. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE et al. RNA-guided human genome engineering via Cas9. Science 2013; 339: 823-826.
37. Lombardo A, Cesana D, Genovese P, Di Stefano B, Provasi E, Colombo DF et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat Methods 2011; 8: 861-869.
38. Leung THY, Ching YP, Yam JWP, Wong CM, Yau TO, Jin DY et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci USA 2005; 102: 15207-15212.
39. Lynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993; 4: 259-272.
40. Hoeben RC, Fallaux FJ, Cramer SJ, van den Wollenberg DJ, van Ormondt H, Briët E et al. Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 1995; 85: 2447-2454.
41. Tagliavacca L, Wang Q, Kaufman RJ. ATP-dependent dissociation of non-disulfide-linked aggregates of coagulation factor VIII is a rate-limiting step for secretion. Biochemistry 2000; 39: 1973-1981.
42. Doering CB, Healey JF, Parker ET, Barrow RT, Lollar P. Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion. J Biol Chem 2004; 279: 6546-6552.
43. Reza HM, Ng BY, Gimeno FL, Phan TT, Ang LPK. Umbilical cord lining stem cells as a novel and promising source for ocular surface regeneration. Stem Cell Rev 2011; 7: 935-947.
44. Zhou Y, Gan SU, Lin G, Lim YT, Masilamani J, Mustafa FB et al. Characterization of human umbilical cord lining derived epithelial cells and transplantation potential. Cell Transplant 2011; 20: 1827-1841.
45. Sclimenti CR, Thyagarajan B, Calos MP. Directed evolution of a recombinase for improved genomic integration at a native human sequence. Nucleic Acids Res 2001; 29: 5044-5051.
46. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25: 402-408.